Oral administration of high-doses of YNKB resulted in significant lipid-lowering activity against hyperlipidemia in apoE-deficient mice, which might be associated with the composition alterations of the gut microbiota and changes in serum metabolite levels. This evidence concerns the gene APOE and hyperlipidemia.